medigraphic.com
ISSN 1561-2937 (Print)

2022, Number 4

<< Back Next >>

Rev Cubana Cardiol Cir Cardiovasc 2022; 28 (4)

Adverse right ventricular remodeling in severe obstetric patients with COVID-19

Tamayo SEA, Silva GML, Cuao MD, Rodríguez FV, Benavides MEM, Chacón MD

Language: Spanish
References: 40
Page: 1-8
PDF size: 501.69 Kb.


ABSTRACT

Introduction: COVID-19 has led to an increased incidence of right ventricular remodeling in severe obstetric patients. Objective: To identify the diagnostic elements that influenced the occurrence of right ventricular remodeling in severe obstetric patients with COVID-19.Methods: A descriptive, cross-sectional, single-center study was performed in 53 severe obstetric patients with COVID-19.Results: The most significant average echocardiographic values were TAPSE (15.4mm), right ventricular end-diastolic diameter (31.3mm) and RV/LV ratio (0.75). An increase in troponins (39.5 ng/L), CPK (338.4 U/L) and CK-MB (51.3 U/L) was observed on admission to the intensive care units, and greater ventricular dilatation and dysfunction were observed in pregnant women with high dímero D (84.6% and 76.9% respectively). AHT (32.07%) was the predominant obstetric risk factor, while patients with bronchial asthma (77.7%) and obesity (69.2%) presented greater dilatation and ventricular dysfunction, respectively. LV ejection fraction constituted the only factor associated with patient survival (p = 0.01).Conclusions: In severe obstetric patients due to COVID-19 decreased TAPSE values and RV dilatation were the main echocardiographic features found. In addition, there was a considerable increase in troponin, CPK and CK-MB values. Greater right ventricular dilatation and dysfunction were recorded in asthmatic and obese women, respectively, with elevated D-dimer values. LV ejection fraction was the only independent factor related to survival in these patients.


REFERENCES

  1. Organización Mundial de la Salud. Informe de la misión conjunta OMS-China sobre la enfermedad por coronavirus 2019 (COVID-19). Ginebra; 2020.

  2. Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383(2):120-8. DOI: https://doi.org/10.1056/NEJMoa2015432

  3. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI: https://doi.org/10.1016/S0140-6736(20)30183-5

  4. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur Heart J. 2020;41(19):1798-800. DOI: https://doi.org/10.1093/eurheartj/ehaa231

  5. Forestieri S, Marcialis MA, Migliore L,Ferrazzi E, Frigerio L, Savasi V, et al. Relación entre embarazo y coronavirus: lo que sabemos. J Matern Fetal Neonatal Med. 2020; 4:1-12. DOI: https://doi.org/10.1080/14767058.2020.

  6. Domínguez Pérez R, Alva Arroyo N, Delgadillo Morales JJ, Enríquez López R, Flores Puente F, Portillo Urbina E, et al. Enfermedad por coronavirus 2019 (COVID-19) pandemia y embarazo. Acta Med. 2020;18(4):399-406. DOI: https://dx.doi.org/10.35366/97267

  7. Rothan HA, ByrareddyS. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. Journal of Autoimmunity 2020;109:102433. DOI: https://doi.org/10.1016/j.jaut.2020.102433

  8. Sola A, Rodríguez S, Cardetti M y Dávila C. COVID-19 perinatal en América Latina. Rev. Panam. Salud Pública. 2020; 47. DOI: https://doi.org/10.26633/RPSP.2020.479

  9. Sitio oficial del Ministerio de Salud pública (MINSAP). Información oficial sobre Coronavirus. La Habana: 2021 [acceso 30/05/2021] Disponible en: https://salud.msp.gob.cu/

  10. Di Renzo GC, Giardina I. Enfermedad de Coronavirus 2019 en el embarazo: consideran trastornos tromboembólicos y la trombosis. Soy J ObstetGynecol. 2020;22(20):30465-8. DOI: https://doi.org/10.1016/j.ajog.2020.04.017

  11. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. DOI: https://doi.org/10.1001/jama.2020.2648

  12. Jering KS, Claggett BL, Cunningham JW,Rosenthal N,Vardeny O, Salomón SD, et al. Clinical characteristics and outcomes of hospitalized women giving birth with and without COVID-19. JAMA Intern Med. 2021;181(5):714-17. Medicine. DOI: https://doi.org/10.1001/jamainternmed.2020.9241

  13. Novel coronavirus 2019 (COVID-19): Practice advisory. The American College of Obstetricians and Gynecologists. 2020 [acceso 23/03/2020]. Disponible en: https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/03/novel-coronavirus-2019.

  14. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):811-8. DOI: https://doi.org/10.1001/jamacardio.2020.1017

  15. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. NatRev Cardiol. 2020;17(5):259-60. DOI: https://doi.org/10.1038/s41569-020-0360-5

  16. (de la) Torre Fonseca LM. Lesión miocárdica en el paciente con COVID-19. CorSalud. 2020 [acceso 15/10/2020];12(2):171-83. Disponible en: http://www.revcorsalud.sld.cu/index.php/cors/article/view/623/1205

  17. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. COVID-19: consider cytokine storm syndromes and immuno-suppression. Lancet. 2020; 395(10229):1033-4. DOI: https://doi.org/10.1016/S0140-6736(20)30628-0

  18. Topol EJ. COVID-19 can affect the heart. SCIENCE (2020);370:6515:408-9.DOI: https://doi.org/10.1126/science.abe2813

  19. Madjid M, Safavi NP, Solomon SD, Vardeny O. Potential effects of coronaviruses on the cardiovascular system: a review. JAMA Cardiol. 2020; 5(7):831-40.DOI:https://doi.org/10.1001/jamacardio.2020.1286

  20. Mesa González M, Correa Padilla JM, Abreu Cruz AA. Complicaciones cardiovasculares en COVID- 19. Boletín científico del CIMEQ. 2020 [acceso 06/11/2020];1(16):6. Disponible en: https://files.sld.cu/cimeq/files/2020/06/Bol-CCimeq-2020-1-16-pag5-6.pdf

  21. 21.Pellikka PA, Naqvi TZ. The Right Ventricle: A Target in COVID-19 Cardiac Insult. J Am Coll Cardiol. 2020; 76(17):1978-81. DOI: https://doi.org/10.1016/j.jacc.2020.09.529

  22. Documento sobre el uso de la ecocardiografía en pacientes con COVID-19. Sociedad Española de Imagen Cardíaca. 2020 [acceso 06/11/2020]. Disponible en :https://ecocardio.com/docs/UsoEcocardiografiaCOVID19.pdf

  23. YLH Li, Zhu S, Xie Y, Sultana R, Kim J, Shaw L, et al. Valor pronóstico de la sobrecarga longitudinal del ventrículo derecho en pacientes con COVID-19. J Am Coll Cardiol. 2020;76(17):1965-77. DOI: https://doi.org/10.1016/j.jacc.2020.08.066

  24. Jiwon K, Volodarskiy A, Sultana R, Pollie M, Yum B, Nambiar L, et al. Prognostic Utility of Right Ventricular Remodeling Over Conventional Risk Stratification in Patients With COVID-19. J Am Coll Cardiol. 2020;76(3):233-46. DOI: https://doi.org/10.1016/j.jacc.2020.08.066

  25. Szekely Y, Lichter Y, Taieb P, Banai A, Hochstadt A, Merdler I, et al. The Spectrum of Cardiac Manifestations in Coronavirus Disease 2019 (COVID-19). A Systematic Echocardiographic Study. Circulation.2020;142:342–53. DOI. https://doi.org/10.1161/CIRCULATIONAHA.120.047971

  26. Zhang G, Zhang J, Wang B, Zhu X, Wang Q, Shiming Q, et al. Analysis of clinical characteristics and laboratory findings of 95 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A retrospective analysis. Respiratory Research. 2020; 21:74 DOI: https://doi.org/10.1186/s12931-020-01338-874

  27. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5(7):802-10. DOI: https://doi.org/10.1001/jamacardio.2020.0950

  28. Munster, VJ, Koopmans, M, van Doremalen, N. Un nuevo coronavirus emergente en China: preguntas clave para la evaluación de impacto. N Engl J Med. 2020 [acceso 22/04/2020];382(8):692–94. Disponible en: https://temas.sld.cu/coronavirus/2020/01/29/un-nuevo-coronavirus-emergen-te-en-china-preguntas-clave-para-la-evaluacion-de-impacto/

  29. Zhou F, Yu T, Du R. Clinical course and risk factors for mortality of adult in patients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020;395(10229):1054-62. DOI: https://doi.org/10.1016/S0140-6736(20)30566-3

  30. 30.Klok FA, Kruip MJHA, Van der Meer NJM, Arbous MS, Kaptein FHJ, Hisman MV, et al. Confirmation of the high cumulative incidence of thrombotic complication in critically ill ICU patients with COVID-19. An updated analysis. Thromb Res 2020;191:148-50. DOI: https://doi.org/10.1016/j.thromres.2020.04.041

  31. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J ThrombHaemost 2020;18:1094-9. DOI: https://doi.org/10.1111/jth.14817

  32. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020;323:2052-9. DOI: https://doi.org/10.1001/jama.2020.6775

  33. Rasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323:1574-81. DOI: https://doi.org/10.1001/jama.2020.5394

  34. Monnet X, SavaleI, Figueiredo S, Gasnier M, Wyplosz B. Etude de cohort comebac–HôpitalBicêtre AP-HP: évaluation des symptômesrésiduels chez 478 patients 4 mois après leurhospitalisation pour COVID-19. JAMA. 2021; 325(15):1525-34 2021. DOI: https://doi.org/10.1001/jama.2021.3331

  35. Entrenas Costa LM, Entrenas Castillo M. Patologías respiratorias crónicas como factor de riesgo de COVID-19. Rev Asma. 2020 [acceso 22/04/2020];5(1):12-9. Disponible en: https://separcontenidos.es/revista3/index.php/revista/article/view/166/234.

  36. BIi Q, Wu Y, Mei S, Ye C, Zou X, Zhang Z, et al. Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: A retrospective cohort study. Lancet Infect Dis. 2020; S1473-3099(20)30287-5. DOI: https://doi.org/10.1016/S1473-3099(20)30287-5

  37. Clerkin KJ, Fried JA, Raikhelkar J, Sayer G, Griffin JM, Masoumi A, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020. DOI: https://doi.org/10.1161/CIRCULATIONAHA.120.046941.16

  38. Rodríguez-Santamarta M, Minguito-Carazo L, Echarte-Morales J, Del Castillo-García S, Valdivia-Ruiz J, Fernández-Vázquez F, et al. Echocardiographic findings in critical patients with COVID-19. Rev Esp Cardiol. 2020;73:861-3. DOI: https://dx.doi.org/10.1016/j.recesp.2020.06.029

  39. Dweck MR, Bularga A, Hahn RT, Donal E, Pearce K, Haugaa C, et al. Global evaluation of echocardiography in patients with COVID-19.Eur Heart J. 2020; 21(9):949-58. DOI: https://doi.org/10.1093/ehjci/jeaa178

  40. González del Hoyo M, Servato L, Rodenas E, Bañeras J, Ferrieras González I, Rodríguez Palomares J, et al. Ecocardiografía en la fase aguda de la infección por COVID-19: impacto en el tratamiento clínico y pronóstico. Rev Esp Card. 2022;75(6). DOI: https://doi.org/10.1016/j.recesp.2021.11.031




2020     |     www.medigraphic.com